Inflammatory and angiogenic factors in the aqueous humor and the relationship to diabetic retinopathy

Current Eye Research

Volumn 35, Issue 12, 2010, Pages 1116-1127

  Oh, In Kyung ^a   Kim, Seong Woo ^a   Oh, Jaeryung ^a   Lee, Tae Soo ^a   Huh, Kuhl ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Diabetic macular edema; Diabetic retinopathy; Interferon induced protein 10; Interleukin 6; Interleukin 8; Monocyte chemoattractant protein 1; Vascular endothelial growth factor

Indexed keywords

ANGIOGENIC FACTOR; CYTOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; TRIAMCINOLONE ACETONIDE; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ADULT; AGED; AQUEOUS HUMOR; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE SEVERITY; HUMAN; NEOVASCULARIZATION (PATHOLOGY); OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DETERMINATION;

ADULT; AGED; ANGIOGENESIS INDUCING AGENTS; AQUEOUS HUMOR; CHEMOKINE CCL2; CYTOKINES; DIABETES COMPLICATIONS; DIABETIC RETINOPATHY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MACULAR EDEMA; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; STATISTICS AS TOPIC; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 78649744741     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713683.2010.510257     Document Type: Article

References (72)

1. Pe'er J, Shweiki D, Itin A, et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest. 1995;72:638-645.
2. Aiello LP, Northrup JM, Keyt BA, et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol. 1995;113:1538-1544.
3. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothe-lial growth factor in ocular fuid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487.
4. Meleth AD, Agron E, Chan CC, et al. Serum infammatory markers in diabetic retinopathy Invest Ophthalmol Vis Sci. 2005;46:4295-4301.
5. Jo N, Wu GS, Rao NA. Upregulation of chemokine expres-sion in the retinal vasculature in ischemia-reperfusion injury. Invest Ophthalmol Vis Sci. 2003;44:4054-4060.
6. Demircan N, Safran BG, Soylu M, et al. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy Eye (Lond). 2006;20:1366-1369.
7. Funatsu H, Yamashita H, Shimizu E, et al. Relationship between vascular endothelial growth factor and interleu-kin-6 in diabetic retinopathy Retina. 2001;21:469-477.
8. Funatsu H, Yamashita H, Noma H, et al. Aqueous humor levels of cytokines are related to vitreous levels and progres-sion of diabetic retinopathy in diabetic patients. Graefes Arch Clin Exp Ophthalmol. 2005;243:3-8.
9. Murugeswari P, Shukla D, Rajendran A, et al. Proinfammatory cytokines and angiogenic and anti-angiogenic factors in vitreous of patients with prolif-erative diabetic retinopathy and Eales' disease. Retina. 2008;28:817-824.
10. Elner SG, Elner VM, Jaffe GJ, et al. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy Curr Eye Res. 1995;14:1045-1053.
11. Elner SG, Strieter R, Bian ZM, et al. Interferon-induced protein 10 and interleukin 8. C-X-C chemokines present in proliferative diabetic retinopathy. Arch Ophthalmol. 1998;116:1597-1601.
12. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fuid. Science. 1983;219:983-985.
13. Murata T, Ishibashi T, Khalil A, et al. Vascular endothelial growth factor plays a role in hyperpermeability of diabetic retinal vessels. Ophthalmic Res. 1995;27:48-52.
14. Funatsu H, Yamashita H, Noma H, et al. Increased levels of vascular endothelial growth factor and interleukin-6 in the aqueous humor of diabetics with macular edema. Am J Ophthalmol. 2002;133:70-77.
15. Joussen AM, Poulaki V, Le ML, et al. A central role for infammation in the pathogenesis of diabetic retinopathy FASEB J. 2004;18:1450-1452.
16. Adamis AP, Berman AJ. Immunological mechanisms in the pathogenesis of diabetic retinopathy Semin Immunopathol. 2008;30:65-84.
17. Lu M, Perez VL, Ma N, et al. VEGF increases retinal vascular ICAM-1 expression in vivo. Invest Ophthalmol Vis Sci. 1999;40:1808-1812.
18. Paccola L, Costa RA, Folgosa MS, et al. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol. 2008;92:76-80.
19. Shimura M, Nakazawa T, Yasuda K, et al. Comparative therapy evaluation of intravitreal bevacizumab and triamcinolone acetonide on persistent diffuse diabetic macular edema. Am J Ophthalmol. 2008;145:854-861.
20. Liu MY, Xydakis AM, Hoogeveen RC, et al. Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 system. Clin Chem. 2005;51:1102-1109.
21. Maier R, Weger M, Haller-Schober EM, et al. Multiplex bead analysis of vitreous and serum concentrations of infammatory and proangiogenic factors in diabetic patients. Mol Vis. 2008;14:637-643.
22. Funding M, Hansen TK, Gjedsted J, et al. Simultaneous quantifcation of 17 immune mediators in aqueous humour from patients with corneal rejection. Acta Ophthalmol Scand. 2006;84:759-765.
23. Curnow SJ, Falciani F, Durrani OM, et al. Multiplex bead immunoassay analysis of aqueous humor reveals distinct cytokine profles in uveitis. Invest Ophthalmol Vis Sci. 2005;46:4251-4259.
24. Yoshimura T, Sonoda K-H, Sugahara M, et al. Comprehensive analysis of infammatory immune mediators in vitreoretinal diseases. PLoS ONE. 2009;4:e8158.
25. Funatsu H, Noma H, Mimura T, et al. Association of vitreous infammatory factors with diabetic macular edema. Ophthalmology. 2009;116:73-79
26. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs\An extension of the modifed Airlie House classifcation. ETDRS report number 10. Ophthalmology. 1991;98:786-806.
27. Fulton RJ, McDade RL, Smith PL, et al. Advanced multiplexed analysis with the FlowMetrix system. Clin Chem. 1997;43:1749-1756.
28. Vignali DA. Multiplexed particle-based fow cytometric assays. J Immunol Methods. 2000;243:243-255.
29. Oppenheim JJ, Zachariae CO, Mukaida N, et al. Properties of the novel proinfammatory supergene "intercrine" cytokine family. Annu Rev Immunol. 1991;9:617-648.
30. Matsushima K, Larsen CG, DuBois GC, et al. Purifcation and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med. 1989;169:1485-1490.
31. Rollins BJ, Walz A, Baggiolini M. Recombinant human MCP-1/JE induces chemotaxis, calcium fux, and the respiratory burst in human monocytes. Blood. 1991;78: 1112-1116.
32. Tashimo A, Mitamura Y, Nagai S, et al. Aqueous levels of macrophage migration inhibitory factor and monocyte chemotactic protein-1 in patients with diabetic retinopathy Diabet Med. 2004;21:1292-1297.
33. Schroder S, Palinski W, Schmid-Schonbein GW. Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy Am J Pathol. 1991;139:81-100.
34. Joussen AM, Murata T, Tsujikawa A, et al. Leukocytemediated endothelial cell injury and death in the diabetic retina. Am J Pathol. 2001;158:147-152.
35. Abu El-Asrar AM, Struyf S, Kangave D, et al. Chemokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy Eur Cytokine Netw. 2006;17: 155-165.
36. Belperio JA, Keane MP, Burdick MD, et al. Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J Clin Invest. 2001;108: 547-556.
37. Inoshima I, Kuwano K, Hamada N, et al. Anti-monocyte chemoattractant protein-1 gene therapy attenuates pulmonary fbrosis in mice. Am J Physiol Lung Cell Mol Physiol. 2004;286:L1038-1044.
38. Wada T, Furuichi K, Sakai N, et al. Gene therapy via blockade of monocyte chemoattractant protein-1 for renal fbrosis. J Am Soc Nephrol. 2004;15:940-948.
39. Gharaee-Kermani M, Denholm EM, Phan SH. Costimulation of fbroblast collagen and transforming growth factor beta1 gene expression by monocyte chemoattractant protein-1 via specifc receptors. J Biol Chem. 1996; 271:17779-17784.
40. Luster AD, Greenberg SM, Leder P. The IP-10 chemokine binds to a specifc cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J Exp Med. 1995;182:219-231.
41. Luster AD, Leder P. IP-10, a-C-X-Cchemokine, elicits a potent thymus-dependent antitumor response in vivo. J Exp Med. 1993;178:1057-1065.
42. Taub DD, Anver M, Oppenheim JJ, et al. T lymphocyte recruitment by interleukin-8 (IL-8). IL-8-induced degranulation of neutrophils releases potent chemoattractants for human T lymphocytes both in vitro and in vivo. J Clin Invest. 1996;97:1931-1941.
43. Kim KS, Rajagopal V, Gonsalves C, et al. A novel role of hypoxia-inducible factor in cobalt chlorideand hypoxiamediated expression of IL-8 chemokine in human endothelial cells. J Immunol. 2006;177:7211-7224.
44. Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 1992;258:1798-1801.
45. Strieter RM, Polverini PJ, Arenberg DA, et al. Role of C-X-C chemokines as regulators of angiogenesis in lung cancer. J Leukoc Biol. 1995;57:752-762.
46. Hernandez C, Segura R, Fonollosa A, et al. Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fuid of patients with proliferative diabetic retinopathy Diabet Med. 2005;22:719-722.
47. Petrovic M, Korosec P, Kosnik M, et al. Vitreous levels of interleukin-8 in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2007;143:175-176.
48. Kopf M, Baumann H, Freer G, et al. Impaired immune and acute-phase responses in interleukin-6-defcient mice. Nature. 1994;368:339-342.
49. Mateo RB, Reichner JS, Albina JE. Interleukin-6 activity in wounds. Am J Physiol Regul Integr Comp Physiol. 1994;266:R1840-R1844.
50. Motro B, Itin A, Sachs L, et al. Pattern of interleukin 6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci USA. 1990;87:3092-3096.
51. Holzinger C, Weissinger E, Zuckermann A, et al. Effects of interleukin-1,-2,-4,-6, interferon-gamma and granulocyte/macrophage colony stimulating factor on human vascular endothelial cells. Immunol Lett. 1993;35:109-117.
52. Mocan MC, Kadayifcilar S, Eldem B. Elevated intravitreal interleukin-6 levels in patients with proliferative diabetic retinopathy Can J Ophthalmol. 2006;41:747-752.
53. Hoekzema R, Murray PI, van Haren MA, et al. Analysis of interleukin-6 in endotoxin-induced uveitis. Invest Ophthalmol Vis Sci. 1991;32:88-95.
54. Murray PI, Hoekzema R, van Haren MA, et al. Aqueous humor interleukin-6 levels in uveitis. Invest Ophthalmol Vis Sci. 1990;31:917-920.
55. Limb GA, Little BC, Meager A, et al. Cytokines in proliferative vitreoretinopathy Eye (Lond). 1991;5(Pt 6):686-693.
56. Kauffmann DJ, van Meurs JC, Mertens DA, et al. Cytokines in vitreous humor: Interleukin-6 is elevated in proliferative vitreoretinopathy Invest Ophthalmol Vis Sci. 1994;35: 900-906.
57. Chen KH, Wu CC, Roy S, et al. Increased interleukin-6 in aqueous humor of neovascular glaucoma. Invest Ophthalmol Vis Sci. 1999;40:2627-2632.
58. Funatsu H, Yamashita H, Ikeda T, et al. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology. 2003;110:1690-1696.
59. Funatsu H, Noma H, Mimura T, et al. Association of vitreous infammatory factors with diabetic macular edema. Ophthalmology. 2009;116:73-79.
60. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306-1309.
61. Antonetti DA, Barber AJ, Khin S, et al. Vascular permeability in experimental diabetes is associated with reduced endothelial occludin content: Vascular endothelial growth factor decreases occludin in retinal endothelial cells. Penn State Retina Research Group. Diabetes. 1998; 47:1953-1959.
62. Murata T, Nakagawa K, Khalil A, et al. The relation between expression of vascular endothelial growth factor and break-down of the blood-retinal barrier in diabetic rat retinas. Lab Invest. 1996;74:819-825.
63. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al. Primary intravitreal bevacizumab (Avastin) for diabetic mac-ular edema: Results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology. 2007;114:743-750.
64. Scott IU, Edwards AR, Beck RW, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114:1860-1867.
65. Elshal MF, McCoy JP. Multiplex bead array assays: Performance evaluation and comparison of sensitivity to ELISA. Methods. 2006;38:317-323.
66. Khan SS, Smith MS, Reda D, et al. Multiplex bead array assays for detection of soluble cytokines: Comparisons of sensitivity and quantitative values among kits from multi-ple manufacturers. Cytometry B Clin Cytom. 2004;61:35-39.
67. Dupont NC, Wang K, Wadhwa PD, et al. Validation and comparison of luminex multiplex cytokine analysis kits with ELISA: Determinations of a panel of nine cytokines in clinical sample culture supernatants. J Reprod Immunol. 2005;66:175-191.
68. Campochiaro PA, Choy DF, Do DV, et al. Monitoring ocular drug therapy by analysis of aqueous samples. Ophthalmology. 2009;116:2158-2164.
69. Pickering JW, Martins TB, Schroder MC, et al. Comparison of a multiplex fow cytometric assay with enzyme-linked immunosorbent assay for quantitation of antibodies to teta-nus, diphtheria, and Haemophilus infuenzae Type b. Clin Diagn Lab Immunol. 2002;9:872-876.
70. Martins TB, Pasi BM, Pickering JW, et al. Determination of cytokine responses using a multiplexed fuorescent microsphere immunoassay Am J Clin Pathol. 2002;118: 346-353.
71. Burgos R, Simo R, Audi L, et al. Vitreous levels of vas-cular endothelial growth factor are not infuenced by its serum concentrations in diabetic retinopathy Diabetologia. 1997;40:1107-1109.
72. Ozturk BT, Bozkurt B, Kerimoglu H, et al. Effect of serum cytokines and VEGF levels on diabetic retinopathy and macular thickness. Mol Vis. 2009;15:1906-1914.